Skip to main content
OpenTrials
Completed

NCT Number: NCT05097222

Impact of Photobiomodulation on Objective, Physiological Measures of Brain Function in Individuals With Post-Concussion Syndrome

Photobiomodulation therapy (PBMT) uses light to influence the mitochondria of cells. PBMT of the brain enhances the metabolic capacity of neurons and stimulates anti-inflammatory, anti-apoptotic, and antioxidant responses, as well as neurogenesis and synaptogenesis. Its therapeutic role in disorders such as dementia and Parkinson's disease, as well as to treat stroke, brain trauma, and depression has gained increasing interest.

BioFlex is a form of PBMT consisting of light-emitting diodes (LEDs) and laser diodes. BioFlex utilizes red and near infrared light which penetrates tissues up to a certain tissue depth and studies have shown stimulates tissue growth and repair at the cellular level. PBMT has been proven useful for the treatment of soft tissue pain. Several studies have shown benefit in using PBMT in the treatment of certain neurological conditions, including chronic, mild traumatic brain injury (mTBI).

The purpose of this exploratory investigation, therefore, is to examine efficacy of BioFlex laser therapy on measures of brain function in patients suffering from PCS after mild-moderate, closed-head, traumatic brain injury cases.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Neurology Studies, Surrey, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, at least 19 years of age or older
  • Diagnosis of persistent post-concussional syndrome after ≥3 months of traumatic brain injury, based on the ICD-10 criteria. This diagnosis should be given to the patient from a clinical practitioner. ICD-10 clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol.
  • Current pharmacologic management can remain stable throughout the protocol.
  • Fluent in English
  • Able to understand the informed consent form, study procedures and willing to participate in study.

Exclusion criteria

  • Malignant skin carcinoma within the treatment area (neck and cranium)
  • Intake of photosensitizing medication.
  • Prior history of PBMT therapy
  • Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder
  • History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke)
  • Diagnosed epilepsy or history of seizures not effectively controlled by medications
  • Exposed to an investigational drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study
  • Pregnant, suspected to be pregnant or planning to become pregnant during the study
  • Contraindicated for the NeuroCatch® Platform 2, including:

9.1. Requires the use of hearing aids or a cochlear implant 9.2. Diagnosed with tinnitus that is currently active 9.3. Has temporary damage to hearing (e.g. punctured ear drum) 9.4. Unable to detect a 740Hz tone played at 85dB in both ears. 9.5. Implanted pacemaker or implanted electrical stimulators 9.6. Metal or plastic implants in the skull, excluding dental/facial implants 9.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 9.8. Previous exposure to the NeuroCatch® Platform 2 audio sequences in the last 3 months

Treatment and study plan

BioFlex Dualport System

Device

The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.

Other names: Photobiomodulation

Sham device

Device

Control

Primary outcomes

  1. Response size of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Event-related potentials (ERPs)

  2. Response timing of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Event-related potentials (ERPs)

Secondary outcomes

  1. Number of adverse events

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Frequency and severity of adverse events

  2. Number of adverse device effects

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Frequency and severity of adverse device effects

  3. Pain Catastrophizing Scale Score

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Mean, standard deviation, and assessment of variance. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.

  4. Rivermead Post-Concussion Symptoms Questionnaire Score

    Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)

    Mean, standard deviation, and assessment of variance. Scored on a scale of 0-64 where higher scores reflect greater severity of post concussive symptoms.

Sponsors and collaborators

Lead sponsor

Dr George Medvedev

Industry

Collaborators

  • MediTech International Inc.

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 28, 2021
Registry last updated
May 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.